Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Ching-Wei David Tzeng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6035-7288; OpenAlex author ID A5076582115. Sources: ClinicalTrials.gov.

Their work

Papers
88 (first author 6, last author 16)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
216
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 12 papers, 1 trial · 2020: 5 papers · 2021: 11 papers · 2022: 10 papers · 2023: 9 papers · 2024: 8 papers · 2025: 8 papers · 2026: 8 papers

Papers 50 of 88

  1. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  2. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  3. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002608↗
  4. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po-25-00703↗
  5. Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18691-x↗
  6. ASO Visual Abstract: Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18865-7↗
  7. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  8. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  9. Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-024-01145-0↗
  10. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  11. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  12. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. First author DOI 10.1097/sla.0000000000006269↗
  13. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  14. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  15. The Landmark Series: Neoadjuvant Therapy for Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-025-17736-5↗
  16. ASO Author Reflections: The Landmark Series-Neoadjuvant Therapy for Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-025-17835-3↗
  17. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  18. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00464-024-11022-3↗
  19. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surg… Co-author DOI 10.1093/bjs/znae033↗
  20. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
  21. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  22. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… Co-author DOI 10.1245/s10434-023-14680-0↗
  23. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Co-author DOI 10.1245/s10434-023-14815-3↗
  24. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  25. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jhbp.1218↗
  26. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05534-3↗
  27. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  28. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  29. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Last author DOI 10.1097/sla.0000000000005184↗
  30. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  31. Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-13758-z↗
  32. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  33. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗
  34. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. Last author DOI 10.1002/jso.26989↗
  35. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  36. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  37. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Last author DOI 10.1016/j.suronc.2021.101673↗
  38. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Co-author DOI 10.1093/jnci/djac018↗
  39. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-21-1248↗
  40. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  41. Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database. Co-author DOI 10.1245/s10434-021-10709-4↗
  42. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  43. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  44. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  45. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. Co-author DOI 10.1002/jso.26394↗
  46. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Last author DOI 10.1002/jso.26650↗
  47. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  48. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Co-author DOI 10.1016/j.pan.2021.03.018↗
  49. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Co-author DOI 10.1016/j.pan.2021.08.006↗
  50. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗

Trials 1

  1. Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery Principal investigator NCT03745794↗

Closest collaborators

The 25 strongest of 216 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 76 shared papers, 2012–2026 · strength 10.37
  2. Michael P. Kim · 49 shared papers, 2017–2026 · strength 6.55
  3. Laura R. Prakash · 42 shared papers, 2017–2026 · strength 6.19
  4. Jeffrey E. Lee · 48 shared papers, 2012–2026 · strength 5.60
  5. Naruhiko Ikoma · 32 shared papers, 2020–2026 · strength 5.31
  6. Robert A. Wolff · 32 shared papers, 2012–2025 · strength 3.57
  7. Eugene Jon Koay · 25 shared papers, 2017–2025 · strength 3.32
  8. Shubham Pant · 18 shared papers, 2019–2025 · strength 2.35
  9. Esther N. Dekker · 8 shared papers, 2024–2026 · strength 2.31
  10. Amer H. Zureikat · 11 shared papers, 2022–2026 · strength 2.25
  11. Bas Groot Koerkamp · 11 shared papers, 2022–2026 · strength 2.25
  12. Marc G. Besselink · 11 shared papers, 2022–2026 · strength 2.25
  13. Alice Chia-Chi Wei · 11 shared papers, 2022–2026 · strength 2.25
  14. Anirban Maitra · 18 shared papers, 2017–2025 · strength 2.21
  15. Rebecca Anne Snyder · 9 shared papers, 2019–2026 · strength 1.97
  16. Huamin Wang · 16 shared papers, 2014–2025 · strength 1.79
  17. Michael James Overman · 12 shared papers, 2017–2025 · strength 1.48
  18. Quisette P. Janssen · 8 shared papers, 2022–2026 · strength 1.45
  19. Ethan Bernard Ludmir · 9 shared papers, 2022–2025 · strength 1.42
  20. Timothy Eric Newhook · 8 shared papers, 2021–2026 · strength 1.41
  21. Eileen Mary O'Reilly · 7 shared papers, 2022–2026 · strength 1.40
  22. Alessandro Paniccia · 7 shared papers, 2022–2026 · strength 1.40
  23. Dan Zhao · 7 shared papers, 2023–2026 · strength 1.24
  24. Milind M. Javle · 12 shared papers, 2015–2024 · strength 1.22
  25. Gauri Rajani Varadhachary · 16 shared papers, 2012–2022 · strength 1.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.